[150 Pages Report] The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.

The respiratory drug delivery market by formulation segment is further divided into device type and formulation type. The types of respiratory drug delivery is categorized into metered dose inhalers, dry powder inhalers, and nebulizers. The dry powder inhalers segment is expected to witness the highest growth during the forecast period due to the advantages associated with the use of these inhalers, such as short administration & preparation time, ease of use, and fewer irritant effects.

The respiratory drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.

Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment accounts for the major share in the market during the forecast period due to increasing prevalence of asthma across the globe.

Currently, North America dominates the pulmonary drug delivery devices market, and Asia represents the second-largest regional market. Moreover, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region.

Prominent players in the respiratory drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

Target Audience:

Pulmonary drug delivery devices and formulation manufacturers

Public and private physicians

Healthcare institutions (Medical data centers)

Research & clinical laboratories

Distributors and suppliers of pulmonary drug delivery devices

Health insurance companies

Market research and consulting firms

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

This report categorizes the respiratory drug delivery market into the following segments and sub segments

Respiratory Drug Delivery Market, by Formulations

Type Suspension Aerosol Solution Aerosol Dry Powder Formulation

Device Type Metered Dose Inhalers (MDI) Dry Powder Inhalers (DPI) Nebulizers



Respiratory Drug Delivery Market, by Canister Type

Plain Canister

Coated Canister

Respiratory Drug Delivery Market, by Applications

Asthma

COPD

Cystic Fibrosis

Respiratory Drug Delivery Market, by End User

Hospitals &Clinics

Homecare settings

Respiratory Drug Delivery Market, by Region

North America U.S. Canada

Europe Germany France U.K. Rest of Europe (RoE)

Asia China India Japan Rest of Asia (RoA)

Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to 5).

Further Split of the RoW Respiratory Drug Delivery Market

market size and growth rate estimates of Latin America, Pacific, and the Middle East & Africa.

The global respiratory drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. The market is witnessing growth due to factors such as increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers, and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis.

The respiratory drug delivery market is segmented based on formulations, canister type, applications, end users, and regions. The formulation segment is further divided into device type and formulation type.

The respiratory drug delivery market, by device type, is categorized into metered dose inhalers, dry powder inhalers, and nebulizers. The metered dose inhalers segment is expected to account for the largest share of the market by type of delivery by device, in 2016. Factors such as the efficient absorption of drugs through the lungs and negligible side effects (as drugs are exposed only to the lungs) are contributing to the growth of this segment.

The respiratory drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.

Based on canister type, the respiratory drug delivery market is segmented into plain canisters and coated canisters. The plain canisters segment is expected to command the largest share of the pulmonary drug delivery devices market in 2016. The market for these canisters is majorly driven by the rising incidence of COPD and increasing use of inhalers

Based on end user, the respiratory drug delivery market is segmented into hospitals & clinics and home care settings. In 2016, the home care settings segment is expected to grow at a highest CAGR of the market due to technological advancements such as digital inhalers in pulmonary drug delivery devices that enable their usage in the home care settings.

Presently, North America dominates the respiratory drug delivery market, and Europe represents the second-largest regional market. This is attributed to increasing technological developments in the form of digital inhalers developed by various companies and supportive reimbursement policies in the form of Medicare and Medicaid.

Prominent players in the respiratory drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst